- Home
- AREB vs KLTO Comparison
AREB vs KLTO Comparison
Compare AREB & KLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AREB
- KLTO
- Stock Information
- Founded
- AREB 2014
- KLTO 2019
- Country
- AREB United States
- KLTO United States
- Employees
- AREB N/A
- KLTO N/A
- Industry
- AREB Plastic Products
- KLTO
- Sector
- AREB Industrials
- KLTO
- Exchange
- AREB Nasdaq
- KLTO NYSE
- Market Cap
- AREB 5.7M
- KLTO 4.8M
- IPO Year
- AREB N/A
- KLTO N/A
- Fundamental
- Price
- AREB $2.48
- KLTO $0.22
- Analyst Decision
- AREB
- KLTO
- Analyst Count
- AREB 0
- KLTO 0
- Target Price
- AREB N/A
- KLTO N/A
- AVG Volume (30 Days)
- AREB 13.7M
- KLTO 31.8M
- Earning Date
- AREB 06-13-2025
- KLTO 05-15-2025
- Dividend Yield
- AREB N/A
- KLTO N/A
- EPS Growth
- AREB N/A
- KLTO N/A
- EPS
- AREB N/A
- KLTO N/A
- Revenue
- AREB $9,887,755.00
- KLTO N/A
- Revenue This Year
- AREB N/A
- KLTO N/A
- Revenue Next Year
- AREB N/A
- KLTO N/A
- P/E Ratio
- AREB N/A
- KLTO N/A
- Revenue Growth
- AREB N/A
- KLTO N/A
- 52 Week Low
- AREB $1.10
- KLTO $0.11
- 52 Week High
- AREB $231.75
- KLTO $13.10
- Technical
- Relative Strength Index (RSI)
- AREB 40.44
- KLTO N/A
- Support Level
- AREB $2.62
- KLTO N/A
- Resistance Level
- AREB $3.05
- KLTO N/A
- Average True Range (ATR)
- AREB 0.45
- KLTO 0.00
- MACD
- AREB 0.18
- KLTO 0.00
- Stochastic Oscillator
- AREB 0.59
- KLTO 0.00
About AREB American Rebel Holdings Inc.
American Rebel Holdings Inc develops self-defense, safe storage, and patriotic product areas using a wholesale distribution network, utilizing personal appearances, musical venue performances, as well as e-commerce and television. It designs, manufactures, and markets concealed carry products. It offers products ranging in Backpacks, jackets, coats, and Others. The Company views its operations and manages its business as one operating segment engaged in patriotic goods, comprised of safes, soft goods, and beer.
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.